Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies
Authors' conclusion
Among patients with ASCVD, hypertriglyceridaemia is common, and is associated with higher ASCVD risk across a range of TG.
Study context
- Population
- Adults with prevalent atherosclerotic cardiovascular disease (ASCVD) and lipid panels, Ontario populationwith ASCVD
- Participants
- 196,717 adults
- Exposure
- Higher vs lower triglyceride levels
- Outcome
- ASCVD events:
- First MI
- Unstable angina
- Stroke or TIA
- Coronary revascularization
- CV death
- Follow-up
- Mean (SD) 2.9 (0.5) years
Main finding
As reported in the abstract
ASCVD events by TG
Composite ASCVD events
24 097
Observational data: associations, not effects.
Further findings
Potential icosapent ethyl eligibility (triglyceride (TG) 135-499 mg/dL and low-density lipoprotein cholesterol (LDLc) 41-100 mg/dL)
- Hypertriglyceridaemia with controlled LDLc
- 25% (49 886)
- Demographically similar to REDUCE-IT with comparable event rates
Original publication
Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J. Published 16 November 2019. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →